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CASE REPORT
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Abstract
Denosumab is a human monoclonal antibody used to prevent skeletal-related events in prostate cancer patients with
bone metastasis. Hypocalcemia ranging from mild to severe requiring prolonged hospitalization have been reported
with the use of denosumab in patients with known risk factors such as chronic kidney disease, vitamin D deﬁciency, low
parathyroid hormone level, hypomagnesemia, extensive osteoblastic metastasis, prior use of bisphosphonates, and
comorbidities impairing calcium absorption. We present a case of a metastatic prostate cancer patient with extensive
osteoblastic metastasis who developed severe recurrent hypocalcemia after a single dose of denosumab requiring a total
of 58 days of high dose intravenous and oral calcium supplementations with three inpatient hospital admissions. This
case highlights the risk of severe hypocalcemia associated with denosumab use even after the disease control with
oncologic therapy and in the absence of other predisposing risk factors. This case also emphasizes monitoring calcium
levels closely in all patients treated with denosumab. In the event of severe hypocalcemia, prolonged hospitalization
should be expected, and discharge planning should be done meticulously, which may help decrease the overall length of
hospital stay, readmissions, and morbidity.
Keywords: Recurrent hypocalcemia, Denosumab, Readmission, Prolonged hospitalization, Metastatic prostate cancer

1. Introduction

P

rostate Cancer is the second most common
cause of cancer death in men, frequently associated with widespread bone metastasis.1,2 Denosumab, a monoclonal antibody against RANKL
(Receptor activator of nuclear factor-kB ligand), is
commonly used for the prevention of skeletalrelated events (SREs) in prostate cancer patients
with bone metastasis which includes pathological
fracture, spinal cord compression, and pain necessitating radiation therapy or surgery.3,4 Hypocalcemia ranging from mild to severe requiring
prolonged hospitalizations has been reported with

the use of denosumab.5e7 Chronic kidney disease
with low GFR (<30 ml/min/1.73sqm), vitamin D
deﬁciency, low parathyroid hormone level (PTH),
hypomagnesemia, extensive osteoblastic metastasis,
prior use of bisphosphonates and comorbidities
impairing calcium absorption (previous intestinal/
bowel surgeries) are known risk factor for hypocalcemia after denosumab use.8e10 The median halflife of denosumab ranges from 25 to 35 days, and
denosumab-induced hypocalcemia usually resolves
within 30 days.11 We present a case of a patient with
metastatic prostate cancer with extensive osteoblastic metastasis who developed severe recurrent
hypocalcemia after a single dose of denosumab
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Table 1. Comparison of labs on the day of presentation Vs. before denosumab administration (5 weeks before the day of presentation).

Hemoglobin
Platelet
Sodium
Creatinine
Blood urea Nitrogen
Calcium
Albumin
Magnesium
Vitamin D 25-OH
Vitamin D 1,25 OH (360.0 (pg/ml)
Alkaline phosphate
Prostate Speciﬁc antigen)
PTH level

Reference range

On the day
of presentation

Before denosumab administration
(5 weeks before day of presentation)

13.5e17.0 gm/dl
150e450  103 ul
135-146 mEq/L
0.5e14.0 mg/dl
7.0e30 mg/dl
8.5e10.4 mg/dl
3.2e4.6 mg/dl
1.5e2.5 mg/dl
20e40 ng/ml
19.9e79.3 pg/ml
20e125 U/L
<4.0 ng/ml
12e88 pg/ml

9.1 mg/dl
126  103/microliter
139 mEq/L
0.55 mg/dl
15 mg/dl
5.0 mg/dl
4.2 mg/dl
2.1 mg/dl
27.0 ng/ml
360 pg/ml
2501 U/L
33.20 ng/ml
239 pg/ml

9.6 gm/dl
164  103/microliter
141 mEq/L
0.59 mg/dl
20 mg/dl
8.5 mg/dl
3.8 mg/dl
Not checked
Not checked
Not checked
884 U/L
>100 ng/ml
Not checked

requiring a total of 58 days of high dose intravenous
and oral calcium supplementations with three
inpatient hospital admissions.

2. Case presentation
A 72-year-old man with the past medical history
of diabetes mellitus on metformin, hypertension on
amlodipine, and two-month history of prostate
cancer with diffuse osseous metastasis who was
treated with androgen deprivation therapy (luteinizing hormone-releasing hormone (LHRH)
agonist/Goserelin; antiandrogen Bicalutamide followed by denosumab 120 mcg subcutaneous after
two weeks of androgen deprivation therapy for
prevention of skeletal-related events presented to
hospital with dizziness, tingling, and numbness of
extremities and perioral area. Vitals on admissions
were blood pressure of 132/62 mmHg, heart rate of
86 bpm, temperature of 36.9-degree Celsius, respiratory rate of 20 breaths per min, and oxygen saturation of 99% on room air. Physical examinations
were unremarkable with negative Chvostek and
Trousseau's signs. Laboratory ﬁndings were significant for hemoglobin 9.1 gm/dl, platelets 126  103/
microliter, sodium 139 mEq/L, creatinine 0.55 mg/
dl, blood urea nitrogen 15 mg/dl, Glomerular
ﬁltration rate (GFR) > 60 ml/min/1.73sqm, calcium
of 5.0 mg/dl, ionized calcium 0.76 mM/L, albumin
4.2 mg/dl, magnesium 2.1 mg/dl, alkaline phosphate
2501 U/L, vitamin D 25-OH 27.0 ng/ml, vitamin D
1,25 OH level 360.0 pg/ml, parathyroid hormone
level 239 pg/ml and prostate-speciﬁc antigen
33.20 ng/ml. The comparison of blood work from
ﬁve weeks ago before denosumab administration
revealed a normal calcium level of 8.5 mg/dl, albumin level of 3.8 mg/dl, and creatinine of 0.55 mg/dl
with elevated prostate-speciﬁc antigen >100 ng/ml

and alkaline phosphate 884 U/L which suggested
denosumab induced hypocalcemia (Table 1). The
electrocardiogram (EKG) demonstrated sinus
rhythm with right bundle branch block and prolonged corrected QTc interval of 491 ms. The patient
reported taking oral calcium 1000 mg daily and
vitamin D 800 U daily after denosumab administration, which his oncologist prescribed.
He was given IV calcium gluconate 4-g bolus
followed by continuous infusion of calcium gluconate 100 mg/ml (10%) 11 g in sodium chloride 0.9%
(1000 ml) at a rate of 50e100 ml/h along with oral
calcium carbonate 5000 mg four times daily and
calcitriol 2 mcg twice a day. Calcium was checked
every 6e8 h on the ﬁrst day, and his calcium levels
improved gradually, and he was discharged on oral
calcium 5000 mg four times daily and calcitriol 0.5
mcg twice a day on the seventh day of hospitalization (Fig. 1). However, after ﬁve days, he presented
back to the emergency room (ER) with similar
symptoms of dizziness and perioral numbness, and
tingling sensations. His calcium level was 5.0 mg/dl
again, and EKG showed sinus rhythm with prolonged Qtc interval 470 ms. He reported compliance
with oral calcium and calcitriol at home. Physical
examinations were unremarkable with negative
Chvostek and Trousseau's signs. He was readmitted
and started on a high-dose continuous infusion of
calcium gluconate 11 g at a rate of 50e100 ml/h. His
calcium levels gradually improved, and calcium
gluconate infusion was gradually decreased to
25 ml/h and stopped. On oral calcium supplementation, his calcium level remained stable for more
than 24 h (Fig. 2). On the ninth day of hospitalization, he was discharged on oral calcium carbonate
5000 mg four times a day, calcitriol 0.5 mcg twice a
day, and ergocalciferol 50,000 IU weekly. His calcium levels were rechecked at the primary care
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Fig. 1. Calcium levels during the ﬁrst hospitalization of 7 days.

clinical decision unit (CDU). A peripherally inserted
central catheter (PICC) line was placed on the 20th
day of hospitalization, and he was discharged home
on the 21st day of hospitalization as his calcium
level remained stable with 6 g of IV calcium gluconate daily. He received 6 g of IV calcium gluconate
daily at CDU for the next 21 days, and his calcium
levels gradually improved (Fig. 4). His calcium
levels remained stable on every other day check for
a week on oral calcium carbonate 5000 mg four
times a day and calcitriol 0.5 mcg twice a day. His
calcium carbonate dose was decreased to 2000 mg
daily and calcitriol to 0.5 mcg daily. His calcium
level remained above 8 mg/dl in follow-up visits.
His hypocalcemia lasted approximately two months,
and he received a high dose of IV calcium gluconate
for about 58 days and had three admissions during
the period.

physician (PCP) ofﬁce four days after the discharge,
and he was noted to have a calcium level of 5.6 mg/
dl and an ionized calcium level of 0.70 mM/L with
an albumin level of 4 mg/dl. He was asymptomatic
during this visit; however, he was readmitted for IV
calcium administration and close monitoring due to
a critically low calcium level. He was restarted on
high-dose IV calcium gluconate along with oral
calcium carbonate and calcitriol as above. His calcium level improved very gradually (Fig. 3). His
urinary calcium was checked on the 14th day of
hospitalization, and it was nil (zero). On the 16th day
of hospitalization, he required approximately 18 g of
IV calcium gluconate per day and 15 g of oral calcium carbonate daily. On the 19th day of hospitalization, his IV calcium gluconate requirement
decreased to approximately 6.6 g per day which
seemed feasible for outpatient administration at
calcium levels mg/dl
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Fig. 2. Calcium levels during the second hospitalization of 9 days.
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Fig. 3. Calcium levels during the third hospitalization of 21 days.
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Fig. 4. Calcium levels at Clinical Decision Unit (CDU) of 21 days after discharge from the third hospitalization.

3. Discussion
Advanced prostate cancer is associated with bone
metastasis in up to 90% of cases which leads to
increased risk of skeletal-related events (SREs) that
includes pain, pathological fracture, hypercalcemia,
and spinal cord compression, necessitating surgery
or radiation therapy leading to signiﬁcant morbidity
and mortality.1,2 The use of osteoclast inhibitors
such as bisphosphonates or denosumab (human
monoclonal antibody against RANKL) can signiﬁcantly reduce the frequency of SREs.3 Denosumab
has become a preferred agent over bisphosphonates
as it has been shown to signiﬁcantly delay time to
SREs compared to bisphosphonates.4 Denosumab
via inhibition of RANKL inhibits osteoclast activity
leading to inhibition of calcium release from bone
which can subsequently cause hypocalcemia.12
In the previously published meta-analysis, the
reported incidence of hypocalcemia from denosumab in a cancer patient with bone metastasis was
5.2% (95% CI from 2.8% to 9.3%), most of which
were mild and asymptomatic but 2% (95% CI from
0.7 to 5.5%) were severe hypocalcemia (corrected
calcium level <7 mg/dl).10 Incidence of all grade
hypocalcemia (Table 2) was higher (14e39.6%) in
observational studies.8,12 The symptoms of hypocalcemia can range from non-speciﬁc symptoms
such as fatigue, hyperirritability to concerning
symptoms of tetany such as perioral numbness,
paresthesia of hands and feet, muscle spasms, carpopedal spasms, laryngospasm, and focal or
generalized seizures. Severe hypocalcemia is
Table 2. Common Terminology Criteria for Adverse Events grading of
hypocalcemia.15
Grade

Total corrected Calcium concentration (mg/dl)

1
2
3
4
5

8.0-Lower limit of Normal
7.0-<8.0
6.0-<7.0
<6.0
If death occurs as a result of hypocalcemia

relatively rare; however, it can be a severe and lifethreatening condition requiring hospitalization and
intravenous calcium administration.13 Severe hypocalcemia has been seen in patients with underlying risk factors such as vitamin D deﬁciency, low
PTH, hypomagnesemia, chronic kidney disease,
extensive osteoblastic metastasis, prior use of
bisphosphonates, and comorbidities impairing calcium absorption (previous intestinal/bowel surgeries).8e10 It has been recommended to use
prophylactic oral calcium 500 mg daily and Vitamin
D 400 IU daily to decrease the risk of hypocalcemia
after denosumab use.4 The recommended treatment
of severe hypocalcemia is intravenous calcium gluconate 1e2-g (90e180 mg of elemental calcium)
bolus followed by continuous infusion 0.5e2.0 mg/
kg/hr @ 5e10 ml/h along with oral calcium, vitamin
D, and calcitriol13,14 The median half-life of denosumab ranges from 25 to 35 days. Denosumabinduced hypocalcemia usually resolves within 30
days.11 Prolonged hospitalization may be necessary
due to the ongoing requirement of high-dose
intravenous calcium, especially in the context of
predisposing risk factors.5e7
Our patient with metastatic prostate cancer with
extensive osseous metastasis had a signiﬁcant risk
for skeletal-related events (SRE). Apart from extensive osteoblastic metastasis, he had no other predisposing risk factor for the development of severe
hypocalcemia. Androgen deprivation therapy
(luteinizing hormone-releasing hormone (LRHR)
agonist/Goserelin, antiandrogen Bicalutamide) was
used for disease control before using denosumab to
decrease the risk of hypocalcemia. After denosumab
administration, he was also compliant with the
prophylactic oral calcium and vitamin D supplementation. Despite the appropriate use of denosumab, he developed severe hypocalcemia and
required prolonged hospitalization with two readmissions after a single dose of denosumab. He
needed 58 days of high-dose intravenous calcium
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supplementation before his calcium levels normalized, demonstrating the increased morbidity and
health care cost that can occur with denosumabinduced hypocalcemia. Several case reports have
been published demonstrating severe prolonged
hypocalcemia after denosumab use,6e8 however to
the best of our knowledge; patients had multiple
underlying risk factors. Hence, we emphasize careful monitoring of serum calcium levels, particularly
in the ﬁrst few weeks of treatment in all patients
treated with denosumab. In the event of severe
hypocalcemia, prolonged hospitalization should be
expected, and discharge planning should be done
meticulously. CDU unit could be utilized as
demonstrated in our case, which could help
decrease hospital length of stay and readmissions.

2.
3.

4.

5.

6.

4. Conclusion
Severe hypocalcemia can occur with a single dose
of denosumab in metastatic prostate cancer patients
even after the disease control with oncologic therapy (chemotherapy, androgen deprivation therapy)
and in the absence of other predisposing risk factors. Hence, it is essential to monitor serum calcium
levels closely in all patients for the ﬁrst few weeks of
treatment. Prolonged hospitalizations should be
expected in case of severe hypocalcemia, and
discharge planning should be done meticulously,
which could help decrease readmissions, hospital
length of stay, and overall morbidity.
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